- Home
- LEGH vs CDNA Comparison
LEGH vs CDNA Comparison
Compare LEGH & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- CDNA
- Stock Information
- Founded
- LEGH 2005
- CDNA 1998
- Country
- LEGH United States
- CDNA United States
- Employees
- LEGH N/A
- CDNA N/A
- Industry
- LEGH Homebuilding
- CDNA Medical Specialities
- Sector
- LEGH Consumer Discretionary
- CDNA Health Care
- Exchange
- LEGH Nasdaq
- CDNA Nasdaq
- Market Cap
- LEGH 646.4M
- CDNA 712.2M
- IPO Year
- LEGH 2018
- CDNA 2014
- Fundamental
- Price
- LEGH $21.61
- CDNA $14.54
- Analyst Decision
- LEGH Strong Buy
- CDNA Buy
- Analyst Count
- LEGH 1
- CDNA 8
- Target Price
- LEGH $29.00
- CDNA $26.86
- AVG Volume (30 Days)
- LEGH 97.2K
- CDNA 1.3M
- Earning Date
- LEGH 11-11-2025
- CDNA 11-03-2025
- Dividend Yield
- LEGH N/A
- CDNA N/A
- EPS Growth
- LEGH 2.38
- CDNA N/A
- EPS
- LEGH 2.23
- CDNA 1.00
- Revenue
- LEGH $184,284,000.00
- CDNA $340,826,000.00
- Revenue This Year
- LEGH $1.51
- CDNA $12.73
- Revenue Next Year
- LEGH $7.92
- CDNA $11.90
- P/E Ratio
- LEGH $9.72
- CDNA $14.57
- Revenue Growth
- LEGH 8.79
- CDNA 14.72
- 52 Week Low
- LEGH $20.85
- CDNA $10.96
- 52 Week High
- LEGH $29.45
- CDNA $31.52
- Technical
- Relative Strength Index (RSI)
- LEGH 19.15
- CDNA 51.03
- Support Level
- LEGH $20.85
- CDNA $13.95
- Resistance Level
- LEGH $27.59
- CDNA $15.50
- Average True Range (ATR)
- LEGH 0.94
- CDNA 0.57
- MACD
- LEGH -0.67
- CDNA -0.09
- Stochastic Oscillator
- LEGH 11.00
- CDNA 32.02
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.